family with sequence similarity 110 member AGenealiases: C20orf55 · bA371L19.3
Q-omics provides the consensus-scored FAM110A profile across patient tissues and cancer cell-line models. FAM110A expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, FAM110A is differentially expressed in 16, with the highest sampling consensus in KIRC. Additionally, FAM110A RNA expression shows 18,591 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight UVM, KIRC, and ACC as cancer lineages where FAM110A shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for FAM110A — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes FAM110A survival associations across molecular data types. FAM110A RNA expression shows survival associations in the most cancer types (27), followed by mutation status (3) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible FAM110A RNA expression–survival associations across cancer types. High FAM110A expression shows unfavorable associations in UVM, COAD, PAAD, MESO and ACC, but favorable associations in KIRC. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for FAM110A RNA expression.
This table summarizes FAM110A tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 16, while mass-spec protein shows differences in 2. The strongest signals are observed in KIRC for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for FAM110A. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. FAM110A shows higher tumor expression in KIRC, HNSC, BLCA, THCA, COAD and LIHC. The KIRC box plot shows higher FAM110A RNA expression in tumor versus normal tissue (log2 FC = +1.082, t-test p < 0.001).
This table shows molecular features associated with FAM110A in patient tissues and cancer cell lines. In patient samples, FAM110A shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, FAM110A RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LARGE_INTESTINE, while CRISPR and shRNA rows add functional-dependency signals in BREAST and SOFT_TISSUE.
